

1. Why is the Company proposing to change its name from “SeQuent Scientific Limited” to “Viyash Scientific Limited”?

Following the recently approved merger of nine group companies with SeQuent, the combined business will operate under a unified platform.

“Viyash Scientific Limited” reflects:

- A stronger, consolidated group identity
- Harmonisation with the Viyash Group brand already known in the pharmaceutical and life-sciences ecosystem
- Better recall in international markets
- Reduction of brand fragmentation across group entities

This name presents a clearer and more consistent identity to customers, regulators, partners, and investors.

2. Does the name change affect my shareholding or rights as a shareholder?

No.

Your shareholding, rights, and privileges remain exactly the same.

The ISIN will also remain unchanged unless SEBI requires a technical modification, in which case you will be notified.

3. Why is the Company proposing changes to the Object Clause of its Memorandum of Association (MOA)?

Post-merger, all businesses of the transferor companies are housed under a single company.

To continue and expand these businesses, the MOA must clearly cover:

- Active Pharmaceutical Ingredients (APIs)
- Intermediates
- Formulations and veterinary products
- Research, testing, and analytical services
- Contract manufacturing and life-sciences services

The revised Objects Clause ensures that the Company is legally empowered to operate the merged businesses efficiently.

4. Will the changes allow the Company to enter unrelated or risky businesses?

No.

The amendments are restricted to activities that are already part of the merged group's existing or related operations.

They **do not** authorize diversification into unrelated sectors or any activity outside the pharma and life-sciences ecosystem.

5. Is the change being made because of any ownership or control change?

No.

There is **no change** in promoter group or management control.

The change is part of the internal restructuring plan already approved by the National Company Law Tribunal (NCLT).

6. How does this change benefit the Company?

- A unified brand improves customer confidence and stakeholder perception
- Stronger positioning for global partnerships

SeQuent - FAQ for Shareholders

(Regarding Postal Ballot for Change of Name and Amendment of Memorandum of Association)

- Simplified regulatory and compliance framework
- Greater operational synergy after consolidation
- Improved ability to introduce new products and services under a single name

7. Will this change impact the Company's financials or ongoing operations?

No negative impact is expected.

Existing manufacturing units, contracts, regulatory filings, and customer arrangements continue without interruption.

Over time, consolidation and a unified brand identity are expected to improve operational efficiencies.

8. What approvals are required for these changes?

The following approvals are necessary:

- Majority approval of shareholders through postal ballot (special resolution)
- Filings with Registrar of Companies
- Compliance with SEBI Listing Regulations
- Effectiveness of the NCLT-approved merger scheme

All necessary documents and certificates have been placed before the Board and are available for inspection (as applicable).

9. How can I cast my vote?

You can vote exclusively through **electronic voting (e-voting)** provided by NSDL.

Your login credentials and instructions are included in the Postal Ballot Notice.

No physical ballot is required.

10. Whom can I contact for queries?

You may write to the Company at

investorrelations@sequent.in

or

contact the Company Secretary at the registered office.